JMM Profile: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Author:

Inglis Timothy J. J.12ORCID,Mathee Kalai3

Affiliation:

1. Department of Microbiology, PathWest Laboratory Medicine, Queen Elizabeth II Medical Centre, Nedlands, WA 6009, Australia

2. Faculty of Health and Medical Sciences, University of Western Australia, Perth, WA 6009, Australia

3. Department of Human and Molecular Genetics, Herbert Wertheim College of Medicine & Biomolecular Sciences Institute, Florida International University, Miami, FL, USA

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus is the cause of an infection known as coronavirus infectious disease 2019 (COVID-19). COVID-19 has become a global source of morbidity, mortality and social disruption since its emergence in East Asia in late 2019 and subsequent pandemic spread. Typical symptoms include cough, sore throat, fever, and sudden loss of taste and smell. Persistent, post-infection sequelae have been noted in a minority of cases. Severe complications and deaths occur mostly in older adults. Laboratory confirmation can be performed by viral RNA and antigen detection in nasal swabs or by detecting specific neutralizing antibodies. There is no effective and approved antiviral treatment, but several vaccines with favourable safety and efficacy profiles are being used in mass vaccination programmes. Vaccine-based COVID control should be seen as an addition to existing hygiene measures such as physical distancing, increased hand hygiene, cough etiquette, and barrier protection with personal protective equipment for frontline healthcare workers and other high-risk professions.

Publisher

Microbiology Society

Subject

Microbiology (medical),General Medicine,Microbiology

Reference9 articles.

1. COVID-19 website. https://www.who.int/emergencies/diseases/novel-coronavirus-2019

2. Laboratory biosafety guidance related to coronavirus disease 2019 (COVID-19). Interim Guidance. https://www.who.int/publications/i/item/laboratorybiosafety-guidance-related-to-coronavirus-disease-(covid-19)

3. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

4. COVID-19 pandemic. https://www.ecdc.europa.eu/en/covid-19-pandemic

5. CDNA National Guidelines for public health units. https://www1.health.gov.au/internet/main/publishing.nsf/Content/cdna-song-novelcoronavirus.htm

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3